This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Albert Einstein College of Medicine, King's College London. Active years: 2021.
Company Filing History:
1 out of 513 
1 out of 196 
Years Active: 2021
Title: Gregory Weitsman: Innovator in Tumor Metastasis Prediction
Introduction
Gregory Weitsman is a notable inventor based in London, GB. He has made significant contributions to the field of cancer research, particularly in understanding tumor metastasis. His innovative work has led to the development of methods that can predict the likelihood of metastatic recurrence in tumors.
Latest Patents
Weitsman holds a patent titled "Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence." This patent outlines methods and products for determining if a subject with a tumor is at risk of metastasis. The methods involve detecting phosphorylated cofilin and quantifying both phosphorylated and non-phosphorylated cofilin. By analyzing the ratio of phosphorylated cofilin to the total amount of cofilin detected, it is possible to assess the risk of metastasis in patients.
Career Highlights
Throughout his career, Gregory Weitsman has worked with prestigious institutions such as the Albert Einstein College of Medicine and King's College London. His research has focused on the mechanisms of tumor progression and the biological markers that indicate metastatic potential.
Collaborations
Weitsman has collaborated with esteemed colleagues, including John S Condeelis and Tony Tsz-Cheong Ng. These partnerships have enhanced the depth and impact of his research in the field of oncology.
Conclusion
Gregory Weitsman's contributions to cancer research through his innovative patent and collaborations highlight his role as a key figure in the fight against metastatic tumors. His work continues to pave the way for advancements in predictive methods for cancer treatment.